Jerini expands collaboration with Baxter to develop non-intraveneous hemophilia therapy
07-Feb-2007
Under the terms of the expanded agreement, Jerini will receive upfront payments and full time equivalents (FTE) funding for each of the two new programs, with potential milestone payments for the achievement of discovery, preclinical, and clinical goals as well as royalties on eventual product sales. The original collaboration between Baxter and Jerini was initiated in 2001 and expanded in 2004.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.